Research & Literature

The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.

Cornec-Le Gall E, Audrézet MP, Rousseau A, et al.

Journal of the American Society of Nephrology : JASN 2016; (27(3)):942-51 doi:10.1681/ASN.2015010016.

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.

Watkins PB, Lewis JH, Kaplowitz N, et al.

Drug safety 2015; (38(11)):1103-13 doi:10.1007/s40264-015-0327-3.

Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease.

Kim H, Park HC, Ryu H, et al.

PloS one 2015; (10(12)):e0144526 doi:10.1371/journal.pone.0144526.

KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetics and Genetic Counseling.

Patel C, Tchan M, Savige J, et al.

Seminars in nephrology 2015; (35(6)):550-556.e1.

KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Polycystic Liver Disease.

Savige J, Mallett A, Tunnicliffe DJ, Rangan GK

Seminars in nephrology 2015; (35(6)):618-622.e5.

A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease.

Kipp KR, Rezaei M, Lin L, et al.

American journal of physiology. Renal physiology 2016; (310(8)):F726-F731 doi:10.1152/ajprenal.00551.2015.

Association between Nephrolithiasis, Hypertension and Obesity in Polycystic Kidney Disease.

Bajrami V, Idrizi A, Roshi E, Barbullushi M

Open access Macedonian journal of medical sciences 2016; (4(1)):43-6 doi:10.3889/oamjms.2016.010.

Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.

Irazabal MV, Abebe KZ, Bae KT, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2017; (32(11)):1857-1865 doi:10.1093/ndt/gfw294.

Autosomal dominant polycystic kidney disease diagnosed in utero. Review.

Nowak M, Huras H, Wiecheć M, et al.

Ginekologia polska 2016; (87(8)):605-8 doi:10.5603/GP.2016.0053.

System analysis of gene mutations and clinical phenotype in Chinese patients with autosomal-dominant polycystic kidney disease.

Jin M, Xie Y, Chen Z, et al.

Scientific reports 2016; (6()):35945 doi:10.1038/srep35945.

The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China.

Xue C, Zhou CC, Wu M, Mei CL

Kidney diseases (Basel, Switzerland) 2016; (2(3)):111-119 doi:10.1159/000449030.

Intracranial aneurysms in patients with autosomal dominant polycystic kidney disease: prevalence, risk of rupture, and management. A systematic review.

Cagnazzo F, Gambacciani C, Morganti R, Perrini P

Acta neurochirurgica 2017; (159(5)):811-821 doi:10.1007/s00701-017-3142-z.

Update on pathogenesis, management, and treatment of hypertension in autosomal dominant polycystic kidney disease.

Helal I, Al-Rowaie F, Abderrahim E, Kheder A

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2017; (28(2)):253-260 doi:10.4103/1319-2442.202774.

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Torres VE, Chapman AB, Devuyst O, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2018; (33(3)):477-489 doi:10.1093/ndt/gfx043.

Is Regular Screening for Intracranial Aneurysm Necessary in Patients with Autosomal Dominant Polycystic Kidney Disease? A Systematic Review and Meta-analysis.

Zhou Z, Xu Y, Delcourt C, et al.

Cerebrovascular diseases (Basel, Switzerland) 2017; (44(1-2)):75-82 doi:10.1159/000476073.

[Quality of life in patients with autosomal dominant polycystic kidney disease].

Lecardeur L, Joly D

Nephrologie & therapeutique 2017; (13(7)):505-510 doi:10.1016/j.nephro.2016.12.005.

New treatment paradigms for ADPKD: moving towards precision medicine.

Lanktree MB, Chapman AB

Nature reviews. Nephrology 2017; (13(12)):750-768 doi:10.1038/nrneph.2017.127.

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.

Cornec-Le Gall E, Blais JD, Irazabal MV, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2018; (33(4)):645-652 doi:10.1093/ndt/gfx188.

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.

Irazabal MV, Blais JD, Perrone RD, et al.

Kidney international reports 2016; (1(4)):213-220 doi:10.1016/j.ekir.2016.08.001.

Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Brosnahan GM, Abebe KZ, Moore CG, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; (71(5)):666-676 doi:10.1053/j.ajkd.2017.10.023.

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations.

Sans-Atxer L, Joly D

International journal of nephrology and renovascular disease 2018; (11()):41-51 doi:10.2147/IJNRD.S125942.

Kidney enlargement and multiple liver cyst formation implicate mutations in PKD1/2 in adult sporadic polycystic kidney disease.

Fujimaru T, Mori T, Sekine A, et al.

Clinical genetics 2018; (94(1)):125-131 doi:10.1111/cge.13249.

Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?

Brosnahan GM, Abebe KZ, Moore CG, et al.

Current hypertension reviews 2018; (14(1)):39-47 doi:10.2174/1573402114666180322110209.

Renal cyst infection: a diagnostic dilemma.

Kamboj M, Zeng X, Koratala A

Clinical case reports 2018; (6(4)):762-763 doi:10.1002/ccr3.1441.

Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer?

Mustafa RA, Yu ASL

Clinical journal of the American Society of Nephrology : CJASN 2018; (13(7)):1107-1109 doi:10.2215/CJN.00190118.

Prevalence of Hypertension in Children with Early-Stage ADPKD.

Massella L, Mekahli D, Paripović D, et al.

Clinical journal of the American Society of Nephrology : CJASN 2018; (13(6)):874-883 doi:10.2215/CJN.11401017.

Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Edwards ME, Chebib FT, Irazabal MV, et al.

Clinical journal of the American Society of Nephrology : CJASN 2018; (13(8)):1153-1161 doi:10.2215/CJN.01520218.

Somatic Mutations in Renal Cyst Epithelium in Autosomal Dominant Polycystic Kidney Disease.

Tan AY, Zhang T, Michaeel A, et al.

Journal of the American Society of Nephrology : JASN 2018; (29(8)):2139-2156 doi:10.1681/ASN.2017080878.

Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.

Higashihara E, Yamamoto K, Kaname S, et al.

Clinical and experimental nephrology 2019; (23(1)):100-111 doi:10.1007/s10157-018-1617-8.

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

Chebib FT, Perrone RD, Chapman AB, et al.

Journal of the American Society of Nephrology : JASN 2018; (29(10)):2458-2470 doi:10.1681/ASN.2018060590.

Autosomal dominant PKD gets an atomic map.

Welling PA

Nature reviews. Nephrology 2018; (14(12)):725-726 doi:10.1038/s41581-018-0066-7.

Progress in the understanding of polycystic kidney disease.

Torres VE, Harris PC

Nature reviews. Nephrology 2019; (15(2)):70-72 doi:10.1038/s41581-018-0108-1.

MRI in autosomal dominant polycystic kidney disease.

Zhang W, Blumenfeld JD, Prince MR

Journal of magnetic resonance imaging : JMRI 2019; (50(1)):41-51 doi:10.1002/jmri.26627.

A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease.

Simms RJ, Doshi T, Metherall P, et al.

European radiology 2019; (29(8)):4188-4197 doi:10.1007/s00330-018-5918-9.

MR Angiography Screening and Surveillance for Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Cost-effectiveness Analysis.

Malhotra A, Wu X, Matouk CC, et al.

Radiology 2019; (291(2)):400-408 doi:10.1148/radiol.2019181399.

Clinical significance of incidentally discovered renal cysts in pediatric patients.

Botwin A, Phewplung T, Wu K, et al.

Abdominal radiology (New York) 2019; (44(8)):2835-2840 doi:10.1007/s00261-019-02017-z.

Identifying gene mutations of Chinese patients with polycystic kidney disease through targeted next-generation sequencing technology.

Wang T, Li Q, Shang S, et al.

Molecular genetics & genomic medicine 2019; (7(6)):e720 doi:10.1002/mgg3.720.

International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people.

Gimpel C, Bergmann C, Bockenhauer D, et al.

Nature reviews. Nephrology 2019; (15(11)):713-726 doi:10.1038/s41581-019-0155-2.

Anterior Cerebral Artery Dissection in a Patient With Autosomal Dominant Polycystic Kidney Disease.

Tanaka M, Takasugi J, Hatate J, et al.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2019; (28(9)):e129-e131 doi:10.1016/j.jstrokecerebrovasdis.2019.06.026.

Intrafamilial Variability of ADPKD.

Lanktree MB, Guiard E, Li W, et al.

Kidney international reports 2019; (4(7)):995-1003 doi:10.1016/j.ekir.2019.04.018.

Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease.

Sanchis IM, Shukoor S, Irazabal MV, et al.

Clinical journal of the American Society of Nephrology : CJASN 2019; (14(8)):1151-1160 doi:10.2215/CJN.14691218.

The ion channel function of polycystin-1 in the polycystin-1/polycystin-2 complex.

Wang Z, Ng C, Liu X, et al.

EMBO reports 2019; (20(11)):e48336 doi:10.15252/embr.201948336.

Native Nephrectomy in Patients With Autosomal Dominant Polycystic Kidney Disease Evaluated for Kidney Transplantation.

Anselmo A, Iaria G, Pellicciaro M, et al.

Transplantation proceedings 2019; (51(9)):2914-2916 doi:10.1016/j.transproceed.2019.08.010.

Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.

Nowak KL, Hopp K

Clinical journal of the American Society of Nephrology : CJASN 2020; (15(4)):577-584 doi:10.2215/CJN.13291019.

Copy Number Variation: A New Genetic Form of Polycystic Kidney and Liver Disease.

Fujimaru T, Sohara E

Kidney international reports 2020; (5(5)):575-576 doi:10.1016/j.ekir.2020.03.007.

Gene Panel Analysis in a Large Cohort of Patients With Autosomal Dominant Polycystic Kidney Disease Allows the Identification of 80 Potentially Causative Novel Variants and the Characterization of a Complex Genetic Architecture in a Subset of Families.

Mantovani V, Bin S, Graziano C, et al.

Frontiers in genetics 2020; (11()):464 doi:10.3389/fgene.2020.00464.

Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) During Pregnancy: Risks and Challenges.

McBride L, Wilkinson C, Jesudason S

International journal of women's health 2020; (12()):409-422 doi:10.2147/IJWH.S204997.

Insights into Autosomal Dominant Polycystic Kidney Disease from Genetic Studies.

Lanktree MB, Haghighi A, di Bari I, et al.

Clinical journal of the American Society of Nephrology : CJASN 2021; (16(5)):790-799 doi:10.2215/CJN.02320220.

Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease.

Riyahi S, Dev H, Blumenfeld JD, et al.

Journal of magnetic resonance imaging : JMRI 2021; (53(2)):564-576 doi:10.1002/jmri.27360.

Biallelic inheritance of hypomorphic PKD1 variants is highly prevalent in very early onset polycystic kidney disease.

Durkie M, Chong J, Valluru MK, et al.

Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(4)):689-697 doi:10.1038/s41436-020-01026-4.

[Cardiovascular disorders in autosomal dominant polycystic kidney disease].

Hamzaoui M, Lamy G, Bellien J, Guerrot D

Nephrologie & therapeutique 2021; (17(1)):18-29 doi:10.1016/j.nephro.2020.09.003.

Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.

Chebib FT, Torres VE

American journal of kidney diseases : the official journal of the National Kidney Foundation 2021; (78(2)):282-292 doi:10.1053/j.ajkd.2020.12.020.

Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.

Shoaf SE, Bricmont P, Repella Gordon J

Clinical and translational science 2021; (14(4)):1535-1542 doi:10.1111/cts.13017.

Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.

Muto S, Okada T, Shibasaki Y, et al.

Clinical and experimental nephrology 2021; (25(9)):1003-1010 doi:10.1007/s10157-021-02083-y.

Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease.

Bellos I

Therapeutics and clinical risk management 2021; (17()):649-656 doi:10.2147/TCRM.S286952.

What are the information needs and concerns of individuals with Polycystic Kidney Disease? Results of an online survey using Facebook and social listening analysis.

Ma T, Lambert K

BMC nephrology 2021; (22(1)):263 doi:10.1186/s12882-021-02472-1.

Birth of two healthy girls following preimplantation genetic diagnosis and gestational surrogacy in a rapidly progressive autosomal dominant polycystic kidney disease case using tolvaptan.

Peces R, Mena R, Peces C, et al.

Clinical kidney journal 2021; (14(8)):1987-1989 doi:10.1093/ckj/sfab082.

Predicting Future Renal Function Decline in Patients with Autosomal Dominant Polycystic Kidney Disease Using Mayo Clinic Classification.

Borrego Utiel FJ, Esteban de la Rosa RJ, Merino García E, et al.

American journal of nephrology 2021; (52(8)):630-641 doi:10.1159/000518255.

Detection of PKD1 and PKD2 Somatic Variants in Autosomal Dominant Polycystic Kidney Cyst Epithelial Cells by Whole-Genome Sequencing.

Zhang Z, Bai H, Blumenfeld J, et al.

Journal of the American Society of Nephrology : JASN 2021; (32(12)):3114-3129 doi:10.1681/ASN.2021050690.

Mayo imaging classification is a good predictor of rapid progress among Korean patients with autosomal dominant polycystic kidney disease: results from the KNOW-CKD study.

Park HC, Hong Y, Yeon JH, et al.

Kidney research and clinical practice 2022; (41(4)):432-441 doi:10.23876/j.krcp.21.261.

Raynaud's phenomenon triggered by the vasopressin V2 receptor antagonist tolvaptan in a patient with autosomal dominant polycystic kidney disease and Sjögren's syndrome.

Roca Oporto FJ, Rocha JL

Clinical kidney journal 2022; (15(4)):827-828 doi:10.1093/ckj/sfab260.

Cilia-Localized Counterregulatory Signals as Drivers of Renal Cystogenesis.

Walker RV, Maranto A, Palicharla VR, et al.

Frontiers in molecular biosciences 2022; (9()):936070 doi:10.3389/fmolb.2022.936070.

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Raina R, Houry A, Rath P, et al.

Drug, healthcare and patient safety 2022; (14()):147-159 doi:10.2147/DHPS.S338050.

The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines.

Patergnani S, Giattino A, Bianchi N, et al.

Biology of the cell 2023; (115(1)):e2200037 doi:10.1111/boc.202200037.

A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease.

Mader G, Mladsi D, Sanon M, et al.

BMC nephrology 2022; (23(1)):334 doi:10.1186/s12882-022-02956-8.

Echocardiographic Abnormalities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients.

Pfeferman MB, Rocha DRD, Rodrigues FG, et al.

Journal of clinical medicine 2022; (11(20)) doi:10.3390/jcm11205982.

Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Sekine A, Hidaka S, Moriyama T, et al.

Journal of clinical medicine 2022; (11(21)) doi:10.3390/jcm11216528.

Autosomal Dominant Polycystic Kidney Disease: Role of Imaging in Diagnosis and Management.

Odedra D, Sabongui S, Khalili K, et al.

Radiographics : a review publication of the Radiological Society of North America, Inc 2023; (43(1)):e220126 doi:10.1148/rg.220126.

Atypical Polycystic Kidney Disease as defined by Imaging.

Iliuta IA, Win AZ, Lanktree MB, et al.

Scientific reports 2023; (13(1)):2952 doi:10.1038/s41598-022-24104-w.

Cardiac Manifestations in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): A Single-Center Study.

Arjune S, Grundmann F, Todorova P, et al.

Kidney360 2023; (4(2)):150-161 doi:10.34067/KID.0002942022.

Mutation Analysis of Autosomal-Dominant Polycystic Kidney Disease Patients.

Suzuki Y, Katayama K, Saiki R, et al.

Genes 2023; (14(2)) doi:10.3390/genes14020443.

Nonpharmacological Management of Autosomal Dominant Polycystic Kidney Disease.

Steele CN, Nowak KL

Advances in kidney disease and health 2023; (30(3)):220-227 doi:10.1053/j.akdh.2022.12.008.

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis.

Lioudis M, Zhou X, Davenport E, et al.

BMC nephrology 2023; (24(1)):182 doi:10.1186/s12882-023-03247-6.

Many lessons still to learn about autosomal dominant polycystic kidney disease.

Orr S, Sayer JA

Journal of rare diseases (Berlin, Germany) 2023; (2(1)):13 doi:10.1007/s44162-023-00017-8.

Case report: Genotype-phenotype characteristics of nine novel PKD1 mutations in eight Chinese patients with autosomal dominant polycystic kidney disease.

Zhuang J, Aierken A, Yalikun D, et al.

Frontiers in medicine 2023; (10()):1268307 doi:10.3389/fmed.2023.1268307.

Assessing the Risk of Progression to Kidney Failure in Patients With Autosomal Dominant Polycystic Kidney Disease.

Lanktree MB, Kline T, Pei Y

Advances in kidney disease and health 2023; (30(5)):407-416 doi:10.1053/j.akdh.2023.06.002.

Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort.

Calvaruso L, Yau K, Akbari P, et al.

Scientific reports 2023; (13(1)):22257 doi:10.1038/s41598-023-48638-9.

Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease.

Oberdhan D, Yarlas A, Bjorner JB, Krasa H

Kidney medicine 2024; (6(1)):100755 doi:10.1016/j.xkme.2023.100755.

Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD.

Bais T, Geertsema P, Knol MGE, et al.

Clinical journal of the American Society of Nephrology : CJASN 2024; (19(5)):591-601 doi:10.2215/CJN.0000000000000427.

Comprehensive Analysis of PKD1 and PKD2 by Long-Read Sequencing in Autosomal Dominant Polycystic Kidney Disease.

Xu D, Mao A, Chen L, et al.

Clinical chemistry 2024; (70(6)):841-854 doi:10.1093/clinchem/hvae030.

Clinical Characteristics and Kidney Outcomes in Chinese Patients with Autosomal Dominant Polycystic Kidney Disease.

Fung WW, Szeto CC, Chow KM, et al.

Kidney360 2024; (5(5)):715-723 doi:10.34067/KID.0000000000000433.

Predictors of autosomal dominant polycystic kidney disease progression: a Brazilian single-center cohort.

Nishimoto IH, Santos AG, Bianchini JM, et al.

Jornal brasileiro de nefrologia 2024; (46(3)):e20230040 doi:10.1590/2175-8239-JBN-2023-0040en.

Mental Health and Autosomal Dominant Polycystic Kidney Disease: A Narrative Review.

Ebrahimi N, Garimella PS, Chebib FT, et al.

Kidney360 2024; (5(8)):1200-1206 doi:10.34067/KID.0000000000000504.

RETRACTED: Determinants of Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Kebede MA, Mengistu YT, Loge BY, et al.

Journal of personalized medicine 2024; (14(9)) doi:10.3390/jpm14090936.

Treatment of Autosomal-Dominant Polycystic Kidney Disease.

Jdiaa SS, Mustafa RA, Yu ASL

American journal of kidney diseases : the official journal of the National Kidney Foundation 2025; (85(4)):491-500 doi:10.1053/j.ajkd.2024.08.008.

Risk factors for unruptured intracranial aneurysms in asymptomatic patients with autosomal dominant polycystic kidney disease: who needs screening? A systematic review and meta-analysis.

Nguyen BA, Halpin B, Olson V, et al.

Journal of neurosurgery 2025; (143(1)):220-231 doi:10.3171/2024.9.JNS241175.

Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease.

Nowak KL, Copeland TP, Ku E, et al.

Clinical journal of the American Society of Nephrology : CJASN 2025; (20(4)):520-528 doi:10.2215/CJN.0000000640.

Autosomal Dominant Polycystic Kidney Disease: A Review.

Chebib FT, Hanna C, Harris PC, et al.

JAMA 2025; (333(19)):1708-1719 doi:10.1001/jama.2025.0310.

Overview of ADPKD in Pregnancy.

Campbell RE, Edelstein CL, Chonchol M

Kidney international reports 2025; (10(4)):1011-1019 doi:10.1016/j.ekir.2024.12.035.

Pain Management in Autosomal Dominant Polycystic Kidney Disease: Clinical Challenges and a Stepwise Algorithmic Approach.

Borghol AH, Munairdjy Debeh FG, Ghanem A, et al.

Kidney360 2025; (6(9)):1618-1631 doi:10.34067/KID.0000000907.

The diagnostic accuracy of ultrasound and genomic tests for the diagnosis of autosomal-dominant polycystic kidney disease: a systematic mapping review.

Harnan S, Gittus M, Falzon L, et al.

Clinical kidney journal 2025; (18(7)):sfaf187 doi:10.1093/ckj/sfaf187.

Reporting ADPK Disease Phenotypes on Abdominal Scans.

Hu Z, Lane EG, Lo GC, et al.

Kidney international reports 2025; (10(9)):2967-2976 doi:10.1016/j.ekir.2025.06.046.

Evaluating gene variations in autosomal dominant polycystic kidney disease patients using whole exome sequencing and phenotype to genotype analysis.

Aypek H, Balaban RF, Huriyet N, et al.

Renal failure 2025; (47(1)):2547306 doi:10.1080/0886022X.2025.2547306.